Rutgers Cancer Institute of New Jersey

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Unveil Wide Range of Innovative Radiation Oncology Research at the 2023 ASTRO Annual Meeting

Retrieved on: 
Friday, September 29, 2023

NEW BRUNSWICK, N.J., Sept. 29, 2023 /PRNewswire/ -- Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present new, novel, and expansive radiation oncology data from their clinical research program at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting, to be held in San Diego from October 1-4.  A total of 10 abstracts have been accepted, comprising clinical data and analyses that advance the understanding and use of radiation therapy in the treatment of lung, breast, pancreatic, and other cancers. Rutgers Cancer Institute and RWJBarnabas Health is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.

Key Points: 
  • Rutgers Cancer Institute and RWJBarnabas Health is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.
  • "We are excited that the physician-scientists from our health system will be presenting significant and valuable information to advance the use of radiotherapy in cancer treatment at this year's ASTRO meeting," said Bruce Haffty, MD, MS, Chair, Radiation Oncology, Associate Vice Chancellor for Cancer Programs at Rutgers Cancer Institute of New Jersey, and System Director of Radiation Oncology at RWJBarnabas Health.
  • Highlights of accepted abstracts include the following:
    Findings of an analysis to explore genetic changes in aggressive pancreatic cancer.
  • The full list of presentations at this year's ASTRO Annual Meeting follows:

Susan G. Komen® To Host MORE THAN PINK Walk in New Jersey This Fall

Retrieved on: 
Tuesday, August 29, 2023

JACKSON, N.J., Aug. 29, 2023 /PRNewswire/ -- Susan G. Komen ®, the world's leading breast cancer organization, today announced it will host a MORE THAN PINK Walk this fall.

Key Points: 
  • JACKSON, N.J., Aug. 29, 2023 /PRNewswire/ -- Susan G. Komen ®, the world's leading breast cancer organization, today announced it will host a MORE THAN PINK Walk this fall.
  • The New Jersey MORE THAN PINK Walk will take place on Saturday, Oct. 7, 2023.
  • The events will raise critical funds that support breast cancer patients, research and patient navigation services to better serve those impacted by the disease.
  • This year's MORE THAN PINK Walk is made possible by the following sponsors: AbbVie, BD, Hackensack Meridian Health, Natera, RWJBarnabas Health Rutgers Cancer Institute of New Jersey, and ShopRite.

MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer

Retrieved on: 
Wednesday, August 16, 2023

MEI Pharma, Inc. (NASDAQ: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the dosing of the first patient in a Phase 1b study evaluating ME-344 in combination with bevacizumab (AVASTIN®) in patients with previously treated metastatic colorectal cancer.

Key Points: 
  • MEI Pharma, Inc. (NASDAQ: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the dosing of the first patient in a Phase 1b study evaluating ME-344 in combination with bevacizumab (AVASTIN®) in patients with previously treated metastatic colorectal cancer.
  • ME-344 is a novel mitochondrial inhibitor targeting energy production through the OXPHOS pathway, which is important for supporting tumor cell survival and proliferation for many forms of cancer, including colorectal cancer.
  • “This clinical study presents an important opportunity to evaluate a novel approach to treatment with the potential to bring improved benefit to patients.
  • This target is quite unlike other treatments for colorectal cancer, and will be studied by investigators at the Rutgers Cancer Institute Metabolomics Center of Excellence in conjunction with the trial.

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health Announce Three Late-Breaking Presentations at the 2023 ASCO Annual Meeting

Retrieved on: 
Thursday, May 25, 2023

NEW BRUNSWICK, N.J., May 25, 2023 /PRNewswire/ -- Rutgers Cancer Institute of New Jersey and RWJBarnabas Health today announced that data from SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL), and two abstracts from the neoadjuvant I-SPY 2 trial evaluating oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer, have been selected as late-breaking presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held both in person in Chicago and online from June 2-6.

Key Points: 
  • "We are thrilled to have physician-scientists from our health system participate in two innovative clinical trials selected for three late-breaking presentations at this year's ASCO annual meeting, reinforcing our commitment to push the boundaries of science, provide patients with cutting-edge treatment options, and transform the way cancer is treated," said Steven K. Libutti, MD, FACS , Director, Rutgers Cancer Institute of New Jersey and Senior Vice President, Oncology Services, RWJBarnabas Health.
  • A total of 33 presentations and 9 publications have been accepted, highlighting research advances in several types of cancer, including lymphoma, pediatric, colorectal and breast cancer.
  • Additionally, researchers observed encouraging anticancer activity of tinengotinib monotherapy in patients with heavily pre-treated solid tumors, including PC, HR+/HER2- BC, TNBC and CCA.
  • The full list of presentations at the 2023 ASCO Annual Meeting follows:

QSAM Biosciences Provides 2022 Update and 2023 Milestones to Shareholders

Retrieved on: 
Tuesday, January 10, 2023

AUSTIN, Texas, Jan. 10, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for the treatment of bone cancer and related diseases, today provides the following update to shareholders regarding progress made in 2022 and milestone goals for 2023.

Key Points: 
  • AUSTIN, Texas, Jan. 10, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for the treatment of bone cancer and related diseases, today provides the following update to shareholders regarding progress made in 2022 and milestone goals for 2023.
  • We are pleased to provide you with an update on QSAM Biosciences’ progress over the last year and what you can expect from us in 2023.
  • We are looking forward to progress in 2023 which we expect will create fundamental value for our shareholders.
  • Thank you again for your support, and from all of us at QSAM, we wish you a happy, healthy and prosperous 2023.

Debbie's Dream Foundation Celebrates a Successful Year of Serving the Stomach Cancer Community Through the Generous Support of Its 2022 Industry Partners

Retrieved on: 
Thursday, December 22, 2022

FORT LAUDERDALE, Fla., Dec. 22, 2022 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) celebrates a successful year of providing critical resources and support to the stomach cancer community. Much of the organization's success is due to the generosity of its 2022 industry partners. In 2022, DDF secured just over $1.6 million in support grants. As a result, the foundation has continued to serve patients, their families, and caregivers through its Patient Resource Education Program (PREP), National and International Symposia, Nutrition Program, and Health Equity Program.

Key Points: 
  • FORT LAUDERDALE, Fla., Dec. 22, 2022 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) celebrates a successful year of providing critical resources and support to the stomach cancer community.
  • Much of the organization's success is due to the generosity of its 2022 industry partners.
  • Through PREP, the foundation provides support and resources through peer-to-peer mentorship, clinical trial matching services, and monthly support groups in partnership with Memorial Cancer Institute.
  • DDF hosted nine Stomach Cancer Educational Webinars, three National Symposia, and one International Symposium in partnership with the Korean Cancer Association.

IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL

Retrieved on: 
Thursday, December 15, 2022

He added: We find it remarkable that we have seen complete responses in this trial in patients that were refractory to prior cellular therapy and other advanced therapies.

Key Points: 
  • He added: We find it remarkable that we have seen complete responses in this trial in patients that were refractory to prior cellular therapy and other advanced therapies.
  • Clinical activity in a highly refractory patient population may represent a path to registration in DLBCL.
  • The VITALIZE Phase 2B trial is a randomized, parallel group, Simon two-stage study designed to assess IMVs lead candidate, MVP-S, in combination with pembrolizumab with or without cyclophosphamide.
  • A Phase 1 clinical trial in bladder cancer, using MVP-S or DPX-SurMAGE, was initiated in early 2022.

Affinity Foundation Announces New Multi-Year Grant Partners, Committing $360,000 Over the Next Three Years

Retrieved on: 
Wednesday, December 14, 2022

The Affinity Foundation and its Board of Trustees are pleased to announce the launch of the Foundations new multi-year grant program.

Key Points: 
  • The Affinity Foundation and its Board of Trustees are pleased to announce the launch of the Foundations new multi-year grant program.
  • We are extremely proud to launch this program, said Karla Wallack, Executive Director of the Affinity Foundation.
  • Multi-year grants provide reliable grant revenue that leads to transformational results, and yet they are incredibly hard to find.
  • The Affinity Foundation is a registered nonprofit organization, you can further our mission by donating today (EIN #20-2706810).

QSAM Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 15, 2022

AUSTIN, Texas, Nov. 15, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for the treatment of bone cancer and related diseases, today announces financial results for the third quarter ended September 30, 2022, as filed with the SEC on November 14, 2022 in the Company’s Form 10-Q, and provides a corporate update.

Key Points: 
  • AUSTIN, Texas, Nov. 15, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam), for the treatment of bone cancer and related diseases, today announces financial results for the third quarter ended September 30, 2022, as filed with the SEC on November 14, 2022 in the Companys Form 10-Q, and provides a corporate update.
  • Approximately $1 million was raised in a common stock / warrant private placement during third quarter.
  • We expect the pace of our clinical trials to accelerate in the fourth quarter of 2022 and into 2023.
  • Our operating expenses were $1.21 million for the third quarter of 2022 as compared to $1.20 million in the 2021 period.

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Showcase Novel and Expansive Hematology/Oncology Data at the 64th American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
Tuesday, November 15, 2022

NEW BRUNSWICK, N.J., Nov. 15, 2022 /PRNewswire/ -- Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present a wide-ranging scope of new hematology/oncology data from their clinical research program at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, being held in New Orleans, Louisiana (and virtually) from December 10-13, 2022. A total of 24 abstracts have been accepted, comprising clinical data and analyses that advance the understanding and treatment of such blood cancers as lymphoma, leukemia and myeloma. Rutgers Cancer Institute, together with RWJBarnabas Health, is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.

Key Points: 
  • A total of 24 abstracts have been accepted, comprising clinical data and analyses that advance the understanding and treatment of such blood cancers as lymphoma, leukemia and myeloma.
  • Rutgers Cancer Institute, together with RWJBarnabas Health, is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.
  • Pola is an antibody-drug conjugate that is safe and effective when combined with chemotherapy in frontline and relapsed, transplant-ineligible DLBCL patients.
  • The full list of presentations at this year's ASH Annual Meeting and Exposition follows: